Gregg Stone, M.D., director of cardiovascular research and education at Columbia University Medical Center / New York-Presbyterian Hospital, explains ABSORB Trial data showing bioresorbable stents had poor outcomes in small coronary vessels. This might be included as a restriction in the instructions for use of the Abbott Absorb stent, which is currently pending FDA final review. Read the related article "Questions Remain on Future of Bioresorbable Stents." Also, read the article "FDA Approves First Totally Bioresorbable Stent."
News | Heart Valve Technology| August 22, 2017
August 22, 2017 — LivaNova PLC announced its Perceval ...
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
News | Stem Cell Therapies| August 16, 2017
August 16, 2017 — BioCardia Inc.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
Feature | Business| August 16, 2017 | Dave Fornell
August 16, 2017 — The Centers for Medicare and Medicaid Services (CMS) announced a proposed rule to reduce the number
News | Clinical Study| August 16, 2017
Aug. 16, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking Clinic
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
News | Cath Lab| August 15, 2017
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
News | Heart Valve Technology| August 09, 2017
Abbott announced that the first patient has been enrolled in a clinical study to evaluate a minimally invasive clip-...